Vincentage Pharma Mulls Hong Kong IPO with $100-200 Million Fundraising Target

Stock News03-26 14:28

Vincentage Pharma, a Chengdu-based pharmaceutical technology company, is reportedly considering a listing on the Hong Kong stock exchange. The company aims to raise between $100 million and $200 million through the offering. Founded in April 2021 by a team of doctors from the Chinese Academy of Sciences, Vincentage Pharma specializes in the research and development of small-molecule chemical drugs and bio-engineered new drugs. Its primary focus is on glucagon-like peptide-1 receptor agonists, targeting areas such as obesity and overweight conditions. The company is also expanding into treatments for typical metabolic diseases, including hypertension and diabetes, as well as atypical metabolic disorders like obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, and Alzheimer's disease. Among its pipeline, the most notable candidate is VCT220, an oral small-molecule GLP-1 receptor agonist also known as CX11. According to public information, CX11 has completed Phase II clinical trials in China, demonstrating competitive weight loss efficacy, and its Phase III trial was initiated by the end of 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150686184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150686184","market":"us","top_or_hot":-1,"title":"Vincentage Pharma Mulls Hong Kong IPO with $100-200 Million Fundraising Target","media":"Stock News","content":"<p>Vincentage Pharma, a Chengdu-based pharmaceutical technology company, is reportedly considering a listing on the Hong Kong stock exchange. The company aims to raise between $100 million and $200 million through the offering. Founded in April 2021 by a team of doctors from the Chinese Academy of Sciences, Vincentage Pharma specializes in the research and development of small-molecule chemical drugs and bio-engineered new drugs. Its primary focus is on glucagon-like peptide-1 receptor agonists, targeting areas such as obesity and overweight conditions. The company is also expanding into treatments for typical metabolic diseases, including hypertension and diabetes, as well as atypical metabolic disorders like obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, and Alzheimer's disease. Among its pipeline, the most notable candidate is VCT220, an oral small-molecule GLP-1 receptor agonist also known as CX11. According to public information, CX11 has completed Phase II clinical trials in China, demonstrating competitive weight loss efficacy, and its Phase III trial was initiated by the end of 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vincentage Pharma Mulls Hong Kong IPO with $100-200 Million Fundraising Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVincentage Pharma Mulls Hong Kong IPO with $100-200 Million Fundraising Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-26 14:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vincentage Pharma, a Chengdu-based pharmaceutical technology company, is reportedly considering a listing on the Hong Kong stock exchange. The company aims to raise between $100 million and $200 million through the offering. Founded in April 2021 by a team of doctors from the Chinese Academy of Sciences, Vincentage Pharma specializes in the research and development of small-molecule chemical drugs and bio-engineered new drugs. Its primary focus is on glucagon-like peptide-1 receptor agonists, targeting areas such as obesity and overweight conditions. The company is also expanding into treatments for typical metabolic diseases, including hypertension and diabetes, as well as atypical metabolic disorders like obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, and Alzheimer's disease. Among its pipeline, the most notable candidate is VCT220, an oral small-molecule GLP-1 receptor agonist also known as CX11. According to public information, CX11 has completed Phase II clinical trials in China, demonstrating competitive weight loss efficacy, and its Phase III trial was initiated by the end of 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1150686184","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150686184","pubTimestamp":1774506505,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Vincentage Pharma, a Chengdu-based pharmaceutical technology company, is reportedly considering a listing on the Hong Kong stock exchange. The company aims to raise between $100 million and $200...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","BK1161":"生物科技","09939":"开拓药业-B","BK1574":"生物医药B类股"},"translate_title":"Vincentage Pharma考虑香港IPO，筹资目标为100-2亿美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1},"content_text":"Vincentage Pharma, a Chengdu-based pharmaceutical technology company, is reportedly considering a listing on the Hong Kong stock exchange. The company aims to raise between $100 million and $200 million through the offering. Founded in April 2021 by a team of doctors from the Chinese Academy of Sciences, Vincentage Pharma specializes in the research and development of small-molecule chemical drugs and bio-engineered new drugs. Its primary focus is on glucagon-like peptide-1 receptor agonists, targeting areas such as obesity and overweight conditions. The company is also expanding into treatments for typical metabolic diseases, including hypertension and diabetes, as well as atypical metabolic disorders like obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, and Alzheimer's disease. Among its pipeline, the most notable candidate is VCT220, an oral small-molecule GLP-1 receptor agonist also known as CX11. According to public information, CX11 has completed Phase II clinical trials in China, demonstrating competitive weight loss efficacy, and its Phase III trial was initiated by the end of 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150686184","isCrawlerRequest":true}